Table 2.
Adverse events associated with NAIs in subjects from the FAERS data.
| SOC terms | Oseltamivir, n (%) (N = 15409) | Laninamivir, n (%) (N = 84) | Peramivir, n (%) (N = 345) | Zanamivir, n (%) (N = 891) |
|---|---|---|---|---|
| Psychiatric disorders | 1880 (12.20) | 2 (2.38) | 4 (1.16) | 81 (9.09) |
| Gastrointestinal disorders | 1786 (11.59) | 18 (21.43) | 22 (6.38) | 56 (6.29) |
| General disorders and administration site conditions | 1875 (12.17) | 7 (8.33) | 32 (9.28) | 113 (12.68) |
| Respiratory, thoracic and mediastinal disorders | 1355 (8.79) | 2 (2.38) | 23 (6.67) | 99 (11.11) |
| Nervous system disorders | 1169 (7.59) | 6 (7.14) | 25 (7.25) | 99 (11.11) |
| Skin and subcutaneous tissue disorders | 672 (4.36) | 2 (2.38) | 12 (3.48) | 32 (3.59) |
| Musculoskeletal and connective tissue disorders | 577 (3.74) | 4 (4.76) | 7 (2.03) | 8 (0.90) |
| Cardiac disorders | 609 (3.95) | 0 | 33 (9.57) | 35 (3.93) |
| Vascular disorders | 448 (2.91) | 4 (4.76) | 32 (9.28) | 41 (4.60) |
| Othersa | 5038 (32.70) | 39 (46.43) | 155 (44.93) | 327 (36.70) |
FAERS, Food and Drug Administration Adverse Event Reporting System; SOC, System Organ Classes; aBlood and lymphatic system disorders, Immune system disorders, Infections and infestations, Injury, poisoning and procedural complications, Metabolism and nutrition disorders, Renal and urinary disorders, etc.